Common-Size Income Statement
Paying user area
Try for free
Allergan PLC pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Allergan PLC for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Allergan PLC, common-size consolidated income statement
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
- Net Revenues and Cost of Sales
- Net revenues remained constant at 100% across all periods. The cost of sales, excluding amortization and impairment, showed a sharp decrease from -31.92% in 2015 to a range between -12.77% and -15.5% from 2016 to 2019, indicating improved cost efficiency in production or procurement after 2015.
- Gross Profit
- Gross profit increased significantly from 68.08% in 2015 to above 84% from 2016 onward, peaking at 87.23% in 2016. This trend aligns with the reduced cost of sales, reflecting stronger underlying profitability before operating expenses.
- Operating Expenses
- Research and development expenses fluctuated between -15.65% and -11.26%, with a general downward trend signaling reduced investment relative to net revenues by 2019. Selling and marketing expenses remained relatively stable, around -19% to -22%. General and administrative expenses showed variability, dropping from -11.72% in 2015 to -8.05% in 2018 but sharply increasing to -15.43% in 2019, suggesting a notable rise in administrative costs at the end of the period.
- Amortization and Impairments
- Amortization costs were substantial and consistently high, ranging from -36.18% to -45.15% over the years, though trending slightly downward by 2019. Goodwill impairments appeared only in 2018 and 2019, with significant negative impacts of -18% and -22.08%, respectively. Impairments on in-process research and development decreased from -9.11% in 2017 to -2.71% by 2019. Net asset sales and impairments were highly volatile, with a notable large negative impact in 2017 (-24.64%) and 2018 (-18.1%), substantially reducing in 2019 (-2.74%).
- Operating Loss and Other Income/Expenses
- Operating loss fluctuated considerably, with the highest loss occurring in 2018 at -39.57%, and an improvement to -27.63% by 2019. Interest income was low but positive, ranging between 0.08% and 0.48%. Interest expense steadily decreased from -7.92% in 2015 to -4.87% in 2019, suggesting either reduced debt levels or more favorable financing costs. Other income and expenses showed high volatility, with a sharp negative in 2017 (-21.56%) but positive or near-zero amounts in other years.
- Profitability and Taxation
- Loss before income taxes showed a highly variable pattern, worsening to -65.16% in 2017 and then improving afterwards but remaining negative. The tax provision displayed irregular behavior, with a large benefit of 41.85% in 2017 and turning slightly negative by 2019 (-0.91%). Net loss from continuing operations worsened markedly from -6.42% in 2016 to above -30% in 2018 and 2019. Net income figures reflected significant volatility, with positive peaks in 2015 and 2016 (above 26% and 102%, respectively) turning to substantial losses during 2017 to 2019, consistent with operational and impairment challenges.
- Other Items
- Income attributable to noncontrolling interest remained minimal and negative throughout, indicating a small detracting effect. Dividends on preferred shares decreased from around -1.9% in 2016 to -0.29% by 2018, with no data reported afterward, possibly reflecting structural changes in capital. Unique items such as goodwill impairments, asset sales impacts, and certain one-time fees contributed significantly to the fluctuations in expense and loss figures.
- Summary
- The data portrays a company experiencing a period of marked volatility between 2015 and 2019. Initial improvements in gross profitability were undermined by high amortization and impairment charges, leading to substantial operating losses from 2017 onward. General and administrative costs rose sharply in the last reported year, contributing further pressure on profitability. While interest expenses decreased, gains were insufficient to offset operating and impairment costs. Overall, the trend points to operational challenges and significant non-cash charges affecting financial outcomes, with persistent net losses in the latter years of the period analyzed.